Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.

Turcano P, Mielke MM, Bower JH, Parisi JE, Cutsforth-Gregory JK, Ahlskog JE, Savica R.

Neurology. 2018 Nov 7. pii: 10.1212/WNL.0000000000006643. doi: 10.1212/WNL.0000000000006643. [Epub ahead of print]

PMID:
30404780
2.

Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.

Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, Graff-Radford N, Ahlskog JE, Uitti RJ, van Gerpen JA, Boeve BF, Parks A, Ross OA, Dickson DW.

Acta Neuropathol. 2018 Jun 20. doi: 10.1007/s00401-018-1878-z. [Epub ahead of print]

PMID:
29926172
3.

Aerobic Exercise: Evidence for a Direct Brain Effect to Slow Parkinson Disease Progression.

Ahlskog JE.

Mayo Clin Proc. 2018 Mar;93(3):360-372. doi: 10.1016/j.mayocp.2017.12.015. Review.

PMID:
29502566
4.

Hyperglycemic chorea/ballism ascertained over 15 years at a referral medical center.

Ryan C, Ahlskog JE, Savica R.

Parkinsonism Relat Disord. 2018 Mar;48:97-100. doi: 10.1016/j.parkreldis.2017.12.032. Epub 2017 Dec 29.

PMID:
29305082
5.

Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.

Whitwell JL, Ahlskog JE, Tosakulwong N, Senjem ML, Spychalla AJ, Petersen RC, Jack CR Jr, Lowe VJ, Josephs KA.

Parkinsonism Relat Disord. 2018 Mar;48:3-9. doi: 10.1016/j.parkreldis.2017.12.016. Epub 2017 Dec 13.

PMID:
29254665
6.

Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?

Coon EA, Ahlskog JE, Silber MH, Fealey RD, Benarroch EE, Sandroni P, Mandrekar JN, Low PA, Singer W.

Parkinsonism Relat Disord. 2018 Mar;48:51-53. doi: 10.1016/j.parkreldis.2017.12.011. Epub 2017 Dec 14.

PMID:
29254663
7.

Cognitive impairment in progressive supranuclear palsy is associated with tau burden.

Koga S, Parks A, Kasanuki K, Sanchez-Contreras M, Baker MC, Josephs KA, Ahlskog JE, Uitti RJ, Graff-Radford N, van Gerpen JA, Wszolek ZK, Rademakers R, Dickson DW.

Mov Disord. 2017 Dec;32(12):1772-1779. doi: 10.1002/mds.27198. Epub 2017 Oct 30.

PMID:
29082658
8.

Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Boeve BF, Graff-Radford J, Rocca WA, Mielke MM.

JAMA Neurol. 2017 Jul 1;74(7):839-846. doi: 10.1001/jamaneurol.2017.0603.

9.

High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970.

Janssen PH, Mandrekar J, Mielke MM, Ahlskog JE, Boeve BF, Josephs K, Savica R.

Mayo Clin Proc. 2017 Jan;92(1):66-71. doi: 10.1016/j.mayocp.2016.09.004. Epub 2016 Dec 12.

10.

Genome-wide gene-environment interaction analysis of pesticide exposure and risk of Parkinson's disease.

Biernacka JM, Chung SJ, Armasu SM, Anderson KS, Lill CM, Bertram L, Ahlskog JE, Brighina L, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2016 Nov;32:25-30. doi: 10.1016/j.parkreldis.2016.08.002. Epub 2016 Aug 3.

11.

Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA.

Mov Disord. 2017 Feb;32(2):227-234. doi: 10.1002/mds.26839. Epub 2016 Oct 25.

12.

The clinical spectrum and natural history of pure akinesia with gait freezing.

Owens E, Josephs KA, Savica R, Hassan A, Klassen B, Bower J, Maraganore D, Matsumoto J, Ahlskog JE.

J Neurol. 2016 Dec;263(12):2419-2423. Epub 2016 Sep 13.

PMID:
27624121
13.

Orthostatic myoclonus associated with Caspr2 antibodies.

van Gerpen JA, Ahlskog JE, Chen R, Fung VS, Hallett M, Gövert F, Deuschl G, Leypoldt F.

Neurology. 2016 Sep 13;87(11):1187-8. doi: 10.1212/WNL.0000000000003140. No abstract available.

PMID:
27621382
14.

Orthostatic tremor: Clinical, electrophysiologic, and treatment findings in 184 patients.

Benito-León J, Domingo-Santos A, Hassan A, Ahlskog JE, Matsumoto JY, Bower JH.

Neurology. 2016 Jul 19;87(3):341. doi: 10.1212/WNL.0000000000002907. No abstract available.

PMID:
27432180
15.

Time Trends in the Incidence of Parkinson Disease.

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA.

JAMA Neurol. 2016 Aug 1;73(8):981-9. doi: 10.1001/jamaneurol.2016.0947.

16.

Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy.

Owens E, Krecke K, Ahlskog JE, Fealey R, Hassan A, Josephs KA, Klassen B, Matsumoto J, Bower J.

Parkinsonism Relat Disord. 2016 Jul;28:107-11. doi: 10.1016/j.parkreldis.2016.05.006. Epub 2016 May 3.

PMID:
27160570
17.

Repetitive exercise dystonia: A difficult to treat hazard of runner and non-runner athletes.

Cutsforth-Gregory JK, Ahlskog JE, McKeon A, Burnett MS, Matsumoto JY, Hassan A, Bower JH.

Parkinsonism Relat Disord. 2016 Jun;27:74-80. doi: 10.1016/j.parkreldis.2016.03.013. Epub 2016 Mar 18.

PMID:
27017145
18.

New and Appropriate Goals for Parkinson Disease Physical Therapy.

Ahlskog JE.

JAMA Neurol. 2016 Mar;73(3):269-70. doi: 10.1001/jamaneurol.2015.4449. No abstract available.

PMID:
26785221
19.

Orthostatic tremor: Clinical, electrophysiologic, and treatment findings in 184 patients.

Hassan A, Ahlskog JE, Matsumoto JY, Milber JM, Bower JH, Wilkinson JR.

Neurology. 2016 Feb 2;86(5):458-64. doi: 10.1212/WNL.0000000000002328. Epub 2016 Jan 8.

PMID:
26747880
20.

Expanding Phenotypic Spectrum of NKX2-1-Related Disorders-Mitochondrial and Immunologic Dysfunction.

Coon EA, Ahlskog JE, Patterson MC, Niu Z, Milone M.

JAMA Neurol. 2016 Feb;73(2):237-8. doi: 10.1001/jamaneurol.2015.2976. No abstract available.

PMID:
26640963
21.

Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms.

Hassan A, Heckman MG, Ahlskog JE, Wszolek ZK, Serie DJ, Uitti RJ, van Gerpen JA, Okun MS, Rayaprolu S, Ross OA.

Parkinsonism Relat Disord. 2016 Jan;22:102-5. doi: 10.1016/j.parkreldis.2015.11.016. Epub 2015 Nov 25.

22.

Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures.

Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, Boeve BF, Lowe V, Ahlskog JE, Shin C, Boes CJ, Crum BA, Laughlin RS, Pittock SJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e161. doi: 10.1212/NXI.0000000000000161. eCollection 2015 Dec.

23.

Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.

Jones AL, Flanagan EP, Pittock SJ, Mandrekar JN, Eggers SD, Ahlskog JE, McKeon A.

JAMA Neurol. 2015 Nov;72(11):1304-12. doi: 10.1001/jamaneurol.2015.2378.

PMID:
26414229
24.

Clinical features and autonomic testing predict survival in multiple system atrophy.

Coon EA, Sletten DM, Suarez MD, Mandrekar JN, Ahlskog JE, Bower JH, Matsumoto JY, Silber MH, Benarroch EE, Fealey RD, Sandroni P, Low PA, Singer W.

Brain. 2015 Dec;138(Pt 12):3623-31. doi: 10.1093/brain/awv274. Epub 2015 Sep 13.

25.

Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies.

Labbé C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, Puschmann A, McCarthy A, Lynch T, Siuda J, Opala G, Rudzinska M, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Sanotsky Y, Rektorová I, McLean PJ, Rademakers R, Ertekin-Taner N, Hassan A, Ahlskog JE, Boeve BF, Petersen RC, Maraganore DM, Adler CH, Ferman TJ, Parisi JE, Graff-Radford NR, Uitti RJ, Wszolek ZK, Dickson DW, Ross OA.

Neurology. 2015 Nov 10;85(19):1680-6. doi: 10.1212/WNL.0000000000001946. Epub 2015 Sep 2. Erratum in: Neurology. 2015 Nov 10;85(19):1728.

26.

Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.

Ahlskog JE.

Mayo Clin Proc. 2014 Jul;89(7):997-1003. doi: 10.1016/j.mayocp.2014.02.018. Review.

PMID:
24996235
27.

Multiple system atrophy: prognostic indicators of survival.

Figueroa JJ, Singer W, Parsaik A, Benarroch EE, Ahlskog JE, Fealey RD, Parisi JE, Sandroni P, Mandrekar J, Iodice V, Low PA, Bower JH.

Mov Disord. 2014 Aug;29(9):1151-7. doi: 10.1002/mds.25927. Epub 2014 Jun 7.

28.

Swiss cheese striatum: clinical implications.

Burnett MS, Witte RJ, Ahlskog JE.

JAMA Neurol. 2014 Jun;71(6):735-41. doi: 10.1001/jamaneurol.2014.286.

PMID:
24733660
29.

Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?

Markopoulou K, Biernacka JM, Armasu SM, Anderson KJ, Ahlskog JE, Chase BA, Chung SJ, Cunningham JM, Farrer M, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2014 Jun;20(6):584-9; discussion 584. doi: 10.1016/j.parkreldis.2014.02.021. Epub 2014 Mar 5.

30.

Clinical and imaging characterization of progressive spastic dysarthria.

Clark HM, Duffy JR, Whitwell JL, Ahlskog JE, Sorenson EJ, Josephs KA.

Eur J Neurol. 2014 Mar;21(3):368-76. doi: 10.1111/ene.12271. Epub 2013 Sep 19.

31.

Incidence of dementia with Lewy bodies and Parkinson disease dementia.

Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA.

JAMA Neurol. 2013 Nov;70(11):1396-402. doi: 10.1001/jamaneurol.2013.3579.

32.

Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives.

Ahlskog JE.

Neurology. 2013 Aug 27;81(9):854. doi: 10.1212/WNL.0b013e3182a39431. No abstract available.

PMID:
23978724
33.

Risk factors for dementia with Lewy bodies: a case-control study.

Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS, Dickson DW, Parisi J, Aakre JA, Geda YE, Knopman DS, Petersen RC, Boeve BF.

Neurology. 2013 Aug 27;81(9):833-40. doi: 10.1212/WNL.0b013e3182a2cbd1. Epub 2013 Jul 26.

34.

Central hyperadrenergic state after lightning strike.

Parsaik AK, Ahlskog JE, Singer W, Gelfman R, Sheldon SH, Seime RJ, Craft JM, Staab JP, Kantor B, Low PA.

Clin Auton Res. 2013 Aug;23(4):169-73. doi: 10.1007/s10286-013-0197-7. Epub 2013 Jun 13.

35.

Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology.

Whitwell JL, Jack CR Jr, Parisi JE, Gunter JL, Weigand SD, Boeve BF, Ahlskog JE, Petersen RC, Dickson DW, Josephs KA.

Eur J Neurol. 2013 Oct;20(10):1417-22. doi: 10.1111/ene.12212. Epub 2013 Jun 7.

36.

Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA.

JAMA Neurol. 2013 Jul;70(7):859-66. doi: 10.1001/jamaneurol.2013.114.

37.

The alien limb phenomenon.

Graff-Radford J, Rubin MN, Jones DT, Aksamit AJ, Ahlskog JE, Knopman DS, Petersen RC, Boeve BF, Josephs KA.

J Neurol. 2013 Jul;260(7):1880-8. doi: 10.1007/s00415-013-6898-y. Epub 2013 Apr 10.

38.

Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions.

Chung SJ, Armasu SM, Anderson KJ, Biernacka JM, Lesnick TG, Rider DN, Cunningham JM, Ahlskog JE, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2013 Jun;19(6):595-9. doi: 10.1016/j.parkreldis.2013.02.008. Epub 2013 Mar 16.

39.

Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder.

Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh M, Adler C, Woodruff B, Beach TG, Iranzo A, Gelpi E, Santamaria J, Tolosa E, Singer C, Mash DC, Luca C, Arnulf I, Duyckaerts C, Schenck CH, Mahowald MW, Dauvilliers Y, Graff-Radford NR, Wszolek ZK, Parisi JE, Dugger B, Murray ME, Dickson DW.

Sleep Med. 2013 Aug;14(8):754-62. doi: 10.1016/j.sleep.2012.10.015. Epub 2013 Mar 7.

40.

Lessons for Parkinson disease from the parkin genotype.

Ahlskog JE.

JAMA Neurol. 2013 May;70(5):551-2. doi: 10.1001/jamaneurol.2013.104. No abstract available.

PMID:
23459925
41.

Autoimmune chorea in adults.

O'Toole O, Lennon VA, Ahlskog JE, Matsumoto JY, Pittock SJ, Bower J, Fealey R, Lachance DH, McKeon A.

Neurology. 2013 Mar 19;80(12):1133-44. doi: 10.1212/WNL.0b013e3182886991. Epub 2013 Feb 20.

42.

Adult-onset opsoclonus-myoclonus syndrome.

Klaas JP, Ahlskog JE, Pittock SJ, Matsumoto JY, Aksamit AJ, Bartleson JD, Kumar R, McEvoy KF, McKeon A.

Arch Neurol. 2012 Dec;69(12):1598-607. doi: 10.1001/archneurol.2012.1173.

PMID:
22986354
43.

Limb immobilization and corticobasal syndrome.

Graff-Radford J, Boeve BF, Drubach DA, Knopman DS, Ahlskog JE, Golden EC, Drubach DI, Petersen RC, Josephs KA.

Parkinsonism Relat Disord. 2012 Dec;18(10):1097-9. doi: 10.1016/j.parkreldis.2012.05.025. Epub 2012 Jun 20.

44.

Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA.

Horm Behav. 2013 Feb;63(2):308-14. doi: 10.1016/j.yhbeh.2012.05.013. Epub 2012 Jun 8.

45.

Metabolic markers or conditions preceding Parkinson's disease: a case-control study.

Savica R, Grossardt BR, Ahlskog JE, Rocca WA.

Mov Disord. 2012 Jul;27(8):974-9. doi: 10.1002/mds.25016. Epub 2012 Jun 1.

46.

Painful legs and moving toes syndrome: a 76-patient case series.

Hassan A, Mateen FJ, Coon EA, Ahlskog JE.

Arch Neurol. 2012 Aug;69(8):1032-8. doi: 10.1001/archneurol.2012.161. Review.

PMID:
22490324
47.

High school football and risk of neurodegeneration: a community-based study.

Savica R, Parisi JE, Wold LE, Josephs KA, Ahlskog JE.

Mayo Clin Proc. 2012 Apr;87(4):335-40. doi: 10.1016/j.mayocp.2011.12.016.

48.

The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy.

Kimpinski K, Iodice V, Burton DD, Camilleri M, Mullan BP, Lipp A, Sandroni P, Gehrking TL, Sletten DM, Ahlskog JE, Fealey RD, Singer W, Low PA.

J Neurol Sci. 2012 Jun 15;317(1-2):92-6. doi: 10.1016/j.jns.2012.02.023. Epub 2012 Mar 14.

49.

Stiff-man syndrome and variants: clinical course, treatments, and outcomes.

McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ.

Arch Neurol. 2012 Feb;69(2):230-8. doi: 10.1001/archneurol.2011.991.

PMID:
22332190
50.

Surgical therapy for multiple sclerosis tremor: a 12-year follow-up study.

Hassan A, Ahlskog JE, Rodriguez M, Matsumoto JY.

Eur J Neurol. 2012 May;19(5):764-8. doi: 10.1111/j.1468-1331.2011.03626.x. Epub 2012 Jan 17.

PMID:
22248187

Supplemental Content

Loading ...
Support Center